Atossa Therapeutics (ATOS) vs Aytu BioPharma (AYTU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aytu BioPharma (AYTU) has outperformed Atossa Therapeutics (ATOS) over the past year, losing 13.5% versus a loss of 83.8%. Over five years, ATOS leads with a -94.3% price change compared with -96.1% for AYTU. Atossa Therapeutics is the larger company by market cap ($24.1 million vs $22.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATOS | AYTU |
|---|---|---|
| Share price | $2.42 | $2.05 |
| Market cap | $24.15M | $22.28M |
| 1-day change | -1.63% | 0.00% |
| YTD return | -72.20% | -21.15% |
| 1-year return | -83.76% | -13.50% |
| 5-year return | -94.27% | -96.13% |
| Forward P/E | — | 13.23 |
| EPS (TTM) | $-4.45 | $-1.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.35 | $3.07 |
| 52-week low | $1.70 | $1.80 |
| Distance from 52-week high | -87.49% | -33.22% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +685.12% | +371.71% |
| Average volume | 64.15K | 34.40K |
| Shares outstanding | 9.98M | 10.87M |
| Employees | 16 | 75 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AYTU has outperformed ATOS by 70.3 percentage points over the past year.
About Atossa Therapeutics
ATOS stock →Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.
Healthcare · Biotechnology · 16 employees
About Aytu BioPharma
AYTU stock →Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age.
Healthcare · Drug Manufacturers - Specialty & Generic · 75 employees
ATOS vs AYTU FAQ
Which is bigger, Atossa Therapeutics or Aytu BioPharma?
Atossa Therapeutics (ATOS) is larger, with a market capitalization of $24.15M compared with $22.28M for Aytu BioPharma (AYTU).
Which stock has performed better over the past year, ATOS or AYTU?
AYTU returned -13.50% over the past 12 months, compared with -83.76% for ATOS (price return, excluding dividends). Past performance does not predict future results.
Are Atossa Therapeutics and Aytu BioPharma in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Atossa Therapeutics and Drug Manufacturers - Specialty & Generic for Aytu BioPharma.